ALPHARETTA, Ga.--(BUSINESS WIRE)--Lori Chmura, CEO of Dune Medical Devices, maker of the successful MarginProbe device, will address investors at the Jefferies Global Healthcare Conference on June 8th, 12.30 ET. The presentation will also be available as a webcast at dunemedical.com/investors. Lori Chmura and Alan Bond, CFO will be available for appointments in New York on June 7th and 8th both before and after the presentation.
Dune Medical Devices is a commercial-stage company revolutionizing cancer diagnosis, surgery, and targeted treatment with its proprietary Radio-Frequency Spectroscopy Technology (RFST) which enables tissue characterization and identification of microscopic residual cancer in real-time. Dune’s first commercial product, MarginProbe®, in routine commercial use in 70 hospitals and in over 15,000 surgeries, has been proven to identify positive margins during breast conservation surgery, enabling surgeons to immediately remove additional microscopic residual cancer, thereby reducing the need for repeat surgeries. The second generation of the RFST, in development, serves as a platform for use in multiple cancer types during diagnosis, surgery, and targeted treatment.
Dune is entering a phase of rapid commercial growth and expansion of its RFST platform for other medical applications.
About Dune Medical Devices
“Imagine not having to wonder, did we get it all?”
At Dune Medical Devices, we believe in reducing the anxiety that waiting for pathology results places on a patient and their families. Our solutions, which are developed on a first-of-its-kind RF Spectroscopy platform, can differentiate cancerous from healthy tissue based on electromagnetic properties, making it possible for patients and physicians to answer the question, “did we get it all?” To learn more about Dune Medical Devices go to http://www.dunemedical.com.
